IngenOx Therapeutics Receives Granted Patents from the EU and China for PRMT5 Inhibitor-based Drugs.

Oxford, UK – 6 October 2023

Download this Press Release as a PDF

IngenOx Therapeutics, the Oxford-based biopharmaceutical company announced today that it had received separate grants of applications from the Chinese (CNIPA); and European Patent Office for compounds and methods useful in the treatment of protein arginine methyl-transferase mediated proliferative disorders such as cancers.

IngenOx is developing oral medicines which inhibit protein arginine methyltransferase 5 (PRMT5), an enzyme that is instrumental in driving the malignant properties of cancer cells. The enzyme methylates key targets which lead to uncontrolled cell growth and division, and inhibitors of PRMT5 are effective at blocking cancer cell proliferation. IngenOx has developed broad intellectual property and has received granted patents covering the PRMT5 enzyme and its inhibitors and is advancing them to clinical trials.

IngenOx’s granted China patent (No ZL201880031972.3) covers a range of tricyclic compounds suitable for use in the treatment of proliferative disorders.  Its European patent (EP3596061) covers compounds useful in the treatment or prevention of a PRMT5-mediated disorder.  

Nick La Thangue, CEO of IngenOx, and Professor of Cancer Biology at the University of Oxford commented:

“We are delighted that the Chinese and European Patent Offices have granted patents on our applications, providing us with wide chemistry cover.  The patents add to and extend our significant intellectual property and patent portfolio and strengthen our competitive position in this increasingly interesting area for cancer drug development. Combined with our precision medicine biomarker approach, we have a very powerful platform for delivering new and effective cancer drugs”.  


About IngenOx Therapeutics

IngenOx Therapeutics is a biopharmaceutical company focused on delivering new precision medicine drugs and vaccines to treat the most difficult cancers, often referred to as cold tumours. It is a spinout from the University of Oxford, and is located in the Oxford Science Park, UK. Its pipeline comprises early to late-stage products that work in different ways to activate the immune response against cold tumours, which are generally poorly recognized by the immune system. An exciting proprietary platform technology focusses on precision cancer vaccines that act by targeting the immune response to a novel source of cancer antigens.

The company’s approach seeks to align the right drug with the right patient enabling a targeted precision medicine approach to cancer therapy. It has also built a proprietary platform around re-educating the body’s immune system to recognise and destroy tumours. The assets in its pipeline have displayed convincing clinical benefits to late-stage cancer patients through disease control, tumour shrinkage, reduced side effects, and extended survival times.

For more information see

Share This Post